Pharvaris to Present at the GA²LEN UCARE Conference 2023

Rhea-AI Summary

Pharvaris (Nasdaq: PHVS) announced the acceptance of one abstract for oral presentation and two abstracts for poster presentation at the GA²LEN UCARE Conference 2023. The company is a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Presentation details include the RAPIDe-1 Phase2 Trial Results, Symptom Relief Definitions in HAE, and Early-Onset Response to Treatment of Hereditary Angioedema Attacks with Deucrictibant. Pharvaris is a bronze level sponsor of the conference, and the presentation slides and posters will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations.

ZUG, Switzerland, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of one abstract for oral presentation and two abstracts for poster presentation at the GA²LEN UCARE Conference 2023, to be held from December 7-9, 2023, at the Rebouças Convention Center in São Paulo, Brazil.

Presentation details:

• Title: Treatment of HAE Attacks with Deucrictibant: RAPIDe-1 Phase2 Trial Results
  Presenter: Markus Magerl, M.D.
  Date/Time: Friday, December 8, 11:18-11:26 a.m. BST (9:18-9:26 a.m. EST)
  Presentation Code: O07
  Type: Oral Presentation
  
  
• Title: Analyzing Symptom Relief Definitions in HAE Using AMRA and PGI-C/PGI-S
  Presenter: Danny M. Cohn, M.D.
  Date/Time: Friday, December 8, 7:00-8:00 p.m. BST (5:00-6:00 p.m. EST)
  Presentation Code: P080
  Type: Happy Poster Hour Presentation
  
  
• Title: Early-Onset Response to Treatment of Hereditary Angioedema Attacks with Deucrictibant
  Presenter: Marcus Maurer, M.D.
  Date/Time: Friday, December 8, 7:00-8:00 p.m. BST (5:00-6:00 p.m. EST)
  Presentation Code: P081
  Type: Happy Poster Hour Presentation
  

Pharvaris is a bronze level sponsor of the GA²LEN UCARE Conference 2023. Following the close of the respective sessions, the presentation slides and posters will be made available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations.

About Pharvaris
Building on its deep-seated roots in HAE, Pharvaris is a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE efficacious, safe, and easy-to-administer alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit https://pharvaris.com/.

FAQ

What is Pharvaris (Nasdaq: PHVS) presenting at the GA²LEN UCARE Conference 2023?

Pharvaris is presenting one abstract for oral presentation and two abstracts for poster presentation, including the RAPIDe-1 Phase2 Trial Results, Symptom Relief Definitions in HAE, and Early-Onset Response to Treatment of Hereditary Angioedema Attacks with Deucrictibant.

When and where will the GA²LEN UCARE Conference 2023 be held?

The conference will be held from December 7-9, 2023, at the Rebouças Convention Center in São Paulo, Brazil.

What is the focus of Pharvaris' presentations at the GA²LEN UCARE Conference 2023?

Pharvaris' presentations will focus on the treatment and prevention of hereditary angioedema (HAE) attacks using novel, oral bradykinin B2 receptor antagonists.

Where can I access Pharvaris' presentation slides and posters from the GA²LEN UCARE Conference 2023?

The presentation slides and posters will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations.